Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas

Van CG, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van ZM et al (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183. doi: 10.1016/S0140-6736(04)15945-X

Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38. doi: 10.1056/NEJMoa062222

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46. doi: 10.1056/NEJMoa054830

Colao A, Di SA, Cappabianca P, Di SC, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033. doi: 10.1056/NEJMoa022657

Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92:2861–2865. doi: 10.1210/jc.2007-0836

Serri O, Chik CL, Ur E, Ezzat S (2003) Diagnosis and management of hyperprolactinemia. CMAJ 169:575–581

Sherlock M, Steeds R, Toogood AA (2007) Dopamine agonist therapy and cardiac valve dysfunction. Clin Endocrinol (Oxf) 67:643–644. doi: 10.1111/j.1365-2265.2007.02974.x

Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777–802. doi: 10.1016/S0894-7317(03)00335-3

Lancellotti P, Livadariu E, Markov M, Daly A, Burlacu MC, Betea D, Pierard L, Beckers A (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1–5

Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. doi: 10.1111/j.1742-1241.2008.01779.x

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265–273. doi: 10.1111/j.1365-2265.2006.02562.x

Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370

Verhelst J, Abs R, Maiter D, Van den BA, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522. doi: 10.1210/jc.84.7.2518

Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534. doi: 10.1210/er.2005-9998

Shimon I, Benbassat C, Hadani M (2007) Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156:225–231. doi: 10.1530/EJE-06-0646

Pastor P, Tolosa E (2003) Cabergoline in the treatment of Parkinson’s disease. Neurologia 18:202–209

Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829. doi: 10.1016/S1474-4422(07)70218-1

Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836–2841